Listed

Alexandria Real Estate Equities, Inc.: Form 10-Q for the period ended Sep 30, 2024

Filed with the SEC on Oct 21, 2024 and accepted by EDGAR at Oct 21, 2024, 16:06 ET.

Share

Management's discussion and analysis

As filed, 89,574 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Forward-looking statements

Certain information and statements included in this quarterly report on Form 10-Q, including, without limitation, statements

containing the words “forecast,” “guidance,” “goals,” “projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,”

“seeks,” “should,” “targets,” or “will,” or the negative of those words or similar words, constitute “forward-looking statements” within the

meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements involve inherent risks and uncertainties regarding events, conditions, and financial trends that

may affect our future plans of operations, business strategy, results of operations, and financial position. A number of important factors

could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including,

but not limited to, the following:

  • Operating factors, such as a failure to operate our business successfully in comparison to market expectations or in

comparison to our competitors, our inability to obtain capital when desired or refinance debt maturities when desired, and/

or a failure to maintain our status as a REIT for federal tax purposes;

  • Market and industry factors, such as adverse developments concerning the life science industry and/or our tenants;
  • Government factors, such as any unfavorable effects resulting from federal, state, local, and/or foreign government

policies, laws, and/or funding levels;

  • Global factors, such as negative economic, social, political, financial, credit market, banking conditions, and/or regional

armed hostilities; and

  • Other factors, such as climate change, cyber intrusions, and/or changes in laws, regulations, and financial accounting

standards.

This list of risks and uncertainties is not exhaustive. Additional information regarding risk factors that may affect us is included

under Part I; “Item 1A. Risk factors”; and “Item 7. Management’s discussion and analysis of financial condition and results of

operations” in our annual report on Form 10-K for the year ended December 31, 2023 and under respective sections in this quarterly

report on Form 10-Q. Readers of this quarterly report on Form 10-Q should also read our other documents filed publicly with the SEC

for further discussion regarding such factors.

45

Overview

We are a Maryland corporation formed in October 1994 that has elected to be taxed as a REIT for federal income tax

purposes. Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science

REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994,

Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science

innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle,

and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North

America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and

one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven

track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic

and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity,

efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our

venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base

that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

As of September 30, 2024:

  • Investment-grade or publicly traded large cap tenants represented 53% of our annual rental revenue;
  • Approximately 96% of our leases (on an annual rental revenue basis) contained effective annual rent escalations

approximating 3% that were either fixed or indexed based on a consumer price index or other index;

  • Approximately 93% of our leases (on an annual rental revenue basis) were triple net leases, which require tenants to pay

substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other

operating expenses (including increases thereto) in addition to base rent;

  • Approximately 92% of our leases (on an annual rental revenue basis) provided for the recapture of capital expenditures

(such as HVAC maintenance and/or replacement, roof replacement, and parking lot resurfacing) that we believe would

typically be borne by the landlord in traditional office leases; and

  • 80% of our leasing activity during the last twelve months was generated from our existing tenant base.

Our primary business objective is to maximize long-term asset value and stockholder returns based on a multifaceted platform

of internal and external growth. A key element of our strategy is our unique focus on Class A/A+ properties located in collaborative

mega campuses in AAA life science innovation clusters. Our mega campuses are designed for scalability, offering our tenants a clear

path for growth, including through our future developments and redevelopments. Strategically located near top academic medical

institutions and equipped with curated amenities, services, and transit access, our mega campuses are designed to support our tenants

in attracting and retaining top talent, which we believe is a key driver of tenant demand for our properties. Our strategy also includes

drawing upon our deep and broad real estate and life science relationships in order to identify and attract new and leading tenants and

to source additional value-creation real estate.

Executive summary

Operating results

Net income attributable to Alexandria’s common stockholders – diluted: Three Months Ended September 30, 2024 2023 Nine Months Ended September 30, 2024 2023
In millions $164.7 $21.9 $374.5 $184.4
Per share $0.96 $0.13 $2.18 $1.08
Funds from operations attributable to Alexandria’s common stockholders – diluted, as adjusted:
In millions $407.9 $386.4 $1,217.3 $1,142.5
Per share $2.37 $2.26 $7.08 $6.69

For additional information, refer to “Funds from operations and funds from operations, as adjusted, attributable to Alexandria

Real Estate Equities, Inc.’s common stockholders” under “Definitions and reconciliations” and to the tabular presentation of these items

in “Results of operations” in Item 2.

46

Continued operational excellence and solid results amid challenging macroeconomics environment

(As of September 30, 2024, unless stated otherwise)
Occupancy of operating properties in North America 94.7%
Percentage of annual rental revenue in effect from mega campuses 76%
Percentage of annual rental revenue in effect from investment-grade or publicly traded large cap tenants 53%
Adjusted EBITDA margin for the three months ended September 30, 2024 70%
Percentage of leases containing annual rent escalations 96%
Weighted-average remaining lease term:
Top 20 tenants 9.5 years
All tenants 7.5 years
Sustained strength in tenant collections:
Tenant receivables as a percentage of rental revenues for the three months ended September 30, 2024 0.9%
October 2024 tenant rents and receivables collected as of the date of this report 99.6%
Tenant rents and receivables for the three months ended September 30, 2024 collected as of the date of this report 99.9%

Strong and flexible balance sheet with significant liquidity; top 10% credit rating ranking among all publicly traded U.S. REITs

  • As of September 30, 2024, our credit ratings from Moody’s Ratings and S&P Global Ratings were Baa1 and BBB+,

respectively, which rank in the top 10% among all publicly traded U.S. REITs.

  • Net debt and preferred stock to Adjusted EBITDA of 5.5x and fixed-charge coverage ratio of 4.4x for the three months ended

September 30, 2024 annualized.

  • Significant liquidity of $5.4 billion.
  • 31% of our total debt matures in 2049 and beyond.
  • 12.6 years weighted-average remaining term of debt.
  • Since 2020, an average of 97.7% of our debt has been fixed rate.
  • Total debt and preferred stock to gross assets of 29%.
  • $1.0 billion of capital contribution commitments from existing consolidated real estate joint venture partners to fund

construction from October 1, 2024 through 2027.

Strong leasing volume and solid rental rates

  • Strong leasing volume aggregating 1.5 million RSF for the three months ended September 30, 2024, up 48% compared to our

previous four-quarter average of 1.0 million RSF.

  • Rental rate changes on lease renewals and re-leasing of space were 5.1% and 1.5% (cash basis) for the three months ended

September 30, 2024 and 16.4% and 8.9% (cash basis) for the nine months ended September 30, 2024.

  • 80% of our leasing activity during the last twelve months was generated from our existing tenant base.
September 30, 2024 Three Months Ended Nine Months Ended
Total leasing activity – RSF 1,486,097 3,742,955
Leasing of development and redevelopment space – RSF 39,121 480,342
Lease renewals and re-leasing of space:
RSF (included in total leasing activity above) 1,278,857 2,863,277
Rental rate changes 5.1% (1) 16.4%
Rental rate changes (cash basis) 1.5% (1) 8.9%

(1) Includes a five-year lease extension to an investment-grade rated technology tenant aggregating 357,136 RSF of recently acquired tech R&D space in our

Texas market that was renewed with rental rate changes of (33.6)% and (4.8)% (cash basis). These spaces were originally targeted for a future change in

use at acquisition, but we instead renewed them with a lower capital investment while we continue to evaluate options to convert these spaces in the future,

subject to market conditions. Excluding this lease, rental rate changes for renewed/re-leased space for the three months ended September 30, 2024 were

13.0% and 2.3% (cash basis).

47

Continued solid net operating income and internal growth

  • Total revenue growth
  • $791.6 million, up 10.9%, for the three months ended September 30, 2024, compared to $713.8 million for the three

months ended September 30, 2023.

  • $2.3 billion, up 9.3%, for the nine months ended September 30, 2024, compared to $2.1 billion for the nine months ended

September 30, 2023.

  • Net operating income (cash basis) of $2.0 billion for the three months ended September 30, 2024 annualized, increased by

$274.2 million, or 15.5%, compared to the three months ended September 30, 2023 annualized. Refer to “Net operating

income, net operating income (cash basis), and operating margin” under “Definitions and reconciliations” in Item 2 for a

reconciliation of our net income to net operating income (cash basis).

  • Same property net operating income growth
  • 1.5% and 6.5% (cash basis) for the three months ended September 30, 2024, compared to the three months ended

September 30, 2023.

  • 1.6% and 4.6% (cash basis) for the nine months ended September 30, 2024, compared to the nine months ended

September 30, 2023.

  • 96% of our leases contain contractual annual rent escalations approximating 3%.

Attractive dividend strategy to share net cash flows from operating activities with stockholders while retaining a significant portion for

reinvestment

  • Common stock dividend declared for the three months ended September 30, 2024 of $1.30 per common share aggregating

$5.14 per common share for the twelve months ended September 30, 2024, up 24 cents, or 5%, over the twelve months

ended September 30, 2023.

  • Dividend yield of 4.4% as of September 30, 2024.
  • Dividend payout ratio of 55% for the three months ended September 30, 2024.
  • Average annual dividend per-share growth of 5.4% from 2020 through the three months ended September 30, 2024

annualized.

  • Significant net cash flows from operating activities after dividends retained for reinvestment aggregating $2.1 billion for the

years ended December 31, 2020 through 2023 and including the midpoint of our 2024 guidance range for net cash provided

by operating activities after dividends.

Ongoing successful execution of Alexandria’s 2024 capital strategy

We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending

December 31, 2024 with dispositions primarily focused on sales of properties and land parcels not integral to our mega campus

strategy. Refer to “Dispositions” in Item 2 for additional details.

(in millions)

Completed dispositions of 100% interest in properties $319
Pending dispositions subject to non-refundable deposits 577
Pending dispositions subject to executed letters of intent and/or purchase and sale agreement 603
Forward equity sales agreements 28
Total $1,527
2024 guidance midpoint for dispositions and common equity $1,550
  • In September 2024, we completed the following transactions with our longstanding tenant, Fred Hutchinson Cancer Center

(“Fred Hutch”), in the Lake Union submarket:

  • Sale of 1165 Eastlake Avenue East, a fully leased 100,086 RSF single-tenant Class A+ life science facility that was

developed in 2021. We sold the property for $150.0 million, or $1,499 per RSF, at strong capitalization rates of 4.7% and

4.9% (cash basis). Upon completion of the sale, we recognized a gain on sale of real estate aggregating $21.5 million.

  • Fred Hutch executed early renewals aggregating 117,479 RSF at our 1201 and 1208 Eastlake Avenue East properties,

including a 15-year lease extension at 1201 Eastlake Avenue East.

  • Our prior joint venture partner sold its ownership interest in each of 1201 and 1208 Eastlake Avenue East to Fred Hutch.

Our ownership interest in both properties remains unchanged at 30.0%. This sale, lease extensions, and new joint venture

affirm Fred Hutch’s commitment to South Lake Union.

48

Strong balance sheet management

Key capital metrics as of or for the three months ended September 30, 2024

September 30, 2024 Quarter Annualized Trailing 12 Months Target for Fourth Quarter of 2024 Annualized
Net debt and preferred stock to Adjusted EBITDA 5.5x 5.6x Less than or equal to 5.1x
Fixed-charge coverage ratio 4.4x 4.5x Greater than or equal to 4.5x
  • $33.1 billion in total market capitalization.
  • $20.5 billion in total equity capitalization, which ranks in the top 10% among all publicly traded U.S. REITs.
  • As of September 30, 2024, our non-real estate investments aggregated $1.5 billion:
  • Unrealized gains presented in our consolidated balance sheet were $166.2 million, comprising gross unrealized gains and

losses aggregating $284.4 million and $118.2 million, respectively.

  • Investment income of $15.2 million for the three months ended September 30, 2024 presented in our consolidated statement

of operations consisted of $23.0 million of realized gains and $2.6 million of unrealized gains, offset by $10.3 million of

impairment charges. Investment income of $14.9 million for the nine months ended September 30, 2024 presented in our

consolidated statement of operations consisted of $85.2 million of realized gains and $32.5 million of unrealized losses, offset

by $37.8 million of impairment charges.

Key capital events

  • In September 2024, we amended and restated our unsecured senior line of credit to, among other changes, extend the

maturity date from January 22, 2028 to January 22, 2030, including extension options that we control.

  • During the three months ended September 30, 2024, we had no activity under our ATM program. As of the date of this report,

the remaining aggregate amount available for future sales of common stock was $1.47 billion.

External growth and investments in real estate

Alexandria’s development and redevelopment pipeline delivered incremental annual net operating income of $21 million, commencing

during the three months ended September 30, 2024, and is expected to deliver incremental annual net operating income aggregating

$510 million primarily by the first quarter of 2028

  • During the three months ended September 30, 2024, we placed into service development and redevelopment projects

aggregating 316,691 RSF that are 100% leased across multiple submarkets and delivered incremental annual net operating

income of $21 million. Deliveries during the three months ended September 30, 2024 included 250,000 RSF at 9820

Darnestown Road on the Alexandria Center® for Life Science – Shady Grove mega campus in our Rockville submarket.

  • Annual net operating income (cash basis) is expected to increase by $57 million upon the burn-off of initial free rent, with a

weighted-average burn-off period of approximately six months, from recently delivered projects.

  • 69% of the RSF in our total development and redevelopment pipeline is within our mega campuses.

(dollars in millions)

Development and Redevelopment Projects Placed into service: Incremental Annual Net Operating Income RSF Leased/ Negotiating Percentage
Six months ended June 30, 2024 $42 628,427 100%
Three months ended September 30, 2024 21 316,691 100
Total placed into service during nine months ended September 30, 2024 $63 945,118 100%
Expected to be placed into service(1):
Fourth quarter of 2024 through fourth quarter of 2025 $158 (2) 5,467,897 55%
First quarter of 2026 through first quarter of 2028 352 (3)
$510

(1) Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed

near-term project expected to commence construction in the next two years.

(2) Includes (i) 1.0 million RSF that is expected to stabilize through 2025 and is 92% leased/negotiating and (ii) expected partial deliveries through fourth quarter of

2025 from projects expected to stabilize in 2026 and beyond. Refer to the initial and stabilized occupancy years under “New Class A/A+ development and

redevelopment properties: current projects” in Item 2 for additional details.

(3) 70% of the leased RSF of our development and redevelopment projects was generated from our existing tenant base.

49

50

Operating summary

Same Property Net Operating Income Growth Rental Rate Growth: Renewed/Re-Leased Space

Margins(1) Favorable Lease Structure(2)

Operating Adjusted EBITDA Strategic Lease Structure by Owner and Operator of Collaborative Mega Campuses

71% 70% Increasing cash flows

Percentage of leases containing annual rent escalations 96%

Stable cash flows

Weighted-Average Lease Term of Executed Leases(3) Percentage of triple net leases 93%

Lower capex burden

8.8 years Percentage of leases providing for the recapture of capital expenditures 92%

Net Debt and Preferred Stock to Adjusted EBITDA(4) Fixed-Charge Coverage Ratio(4)

Refer to “Same properties” and “Definitions and reconciliations” in Item 2 for additional details. “Definitions and reconciliations” contains the definitions of “Fixed-charge

coverage ratio,” “Net debt and preferred stock to Adjusted EBITDA,” and “Net operating income” and their respective reconciliations from the most directly comparable

financial measures presented in accordance with GAAP.

(1) For the three months ended September 30, 2024.

(2) Percentages calculated based on our annual rental revenue in effect as of September 30, 2024.

(3) Represents the weighted-average lease term of executed leases based on annual rental revenue for the 10-year period from December 31, 2015 through September 30,

(4) Quarter annualized.

51

Stable Cash Flows From Our High-Quality and Diverse Mix of Approximately 800 Tenants
Investment-Grade or Publicly Traded Large Cap Tenants
92%
of ARE’s Top 20 Tenant Annual Rental Revenue
53%
of ARE’s Annual Rental Revenue
Percentage of ARE’s Annual Rental Revenue
Solid Historical Occupancy of 96% Over Past 10 Years(2) From Historically Strong Demand for Our Class A/A+ Properties in AAA Locations
Mega Campuses Occupancy Across Key Locations
Percentage of ARE’s Annual Rental Revenue

(3)

Life Science

Product,

Service, and

Device

Multinational

Pharmaceutical

Public

Biotechnology –

Approved or

Marketed

Product

Public

Biotechnology –

Preclinical or

Clinical Stage

Private

Biotechnology

Other(1)

Other Investment-Grade

or Large Cap Tech

Biomedical and

Government

Institutions

76%

Mega

Campuses

24%

Non-Mega

Campuses

As of September 30, 2024. Annual rental revenue represents amounts in effect as of September 30, 2024. Refer to “Definitions and reconciliations” in Item 2 for additional

information.

(1) Represents the percentage of our annual rental revenue generated by technology, professional services, finance, telecommunications, and construction/real estate

companies, as well as retail-related tenants, which generate less than 1.0% of our annual rental revenue.

(2) Represents average occupancy of operating properties as of each December 31 from 2015 through 2023 and as of September 30, 2024.

(3) Refer to footnote 1 under “Summary of occupancy percentages in North America” in Item 2 for additional details.

52

Long-Duration and Stable Cash Flows From High-Quality and Diverse Tenants

Long-Duration Lease Terms

9.5 Years

Top 20 Tenants

7.5 Years

All Tenants

Weighted-Average Remaining Term(1)

Sustained Strength in Tenant Collections(2)

99.9%

For the Three Months Ended September 30, 2024

99.6%

October 2024

(1) Based on annual rental revenue in effect as of September 30, 2024.

(2) Represents the portion of total receivables billed for each period collected through the date of this report.

53

Leasing Activity

The following table summarizes our leasing activity at our properties:

(Dollars per RSF) Leasing activity: Renewed/re-leased space(1) Three Months Ended September 30, 2024 Including Straight-Line Rent Cash Basis Nine Months Ended September 30, 2024 Including Straight-Line Rent Cash Basis Year Ended December 31, 2023 Including Straight-Line Rent Cash Basis
Rental rate changes 5.1% (2) 1.5% (2) 16.4% 8.9% 29.4% 15.8%
New rates $56.60 $55.77 $63.43 $62.39 $52.35 $50.82
Expiring rates $53.86 $54.95 $54.47 $57.28 $40.46 $43.87
RSF 1,278,857 2,863,277 3,046,386
Tenant improvements/ leasing commissions $43.73 (3) $33.92 $26.09
Weighted-average lease term 9.7 years 8.7 years 8.7 years
Developed/redeveloped/ previously vacant space leased(4)
New rates $52.66 $52.18 $64.59 $62.90 $65.66 $59.74
RSF 207,240 879,678 (5) 1,259,686
Weighted-average lease term 10.6 years 8.1 years 13.8 years
Leasing activity summary (totals):
New rates $56.05 $55.27 $63.69 $62.50 $56.09 $53.33
RSF 1,486,097 3,742,955 4,306,072
Weighted-average lease term 9.8 years 8.6 years 11.3 years
Lease expirations(1)
Expiring rates $51.62 $53.17 $52.01 $54.40 $43.84 $45.20
RSF 1,500,213 3,801,559 5,027,773

Leasing activity includes 100% of results for properties in North America in which we have an investment.

(1) Excludes month-to-month leases aggregating 355,698 RSF and 86,092 RSF as of September 30, 2024 and December 31, 2023, respectively. Month-to-month leases

aggregating 355,698 RSF as of September 30, 2024 include 226,144 RSF in our University Town Center submarket primarily related to space being temporarily held over

by an expiring tenant at buildings that are targeted for the future development of laboratory space, subject to market conditions and leasing. During the trailing twelve

months ended September 30, 2024, we granted free rent concessions averaging 0.7 months per annum.

(2) Includes a five-year lease extension to an investment-grade rated technology tenant aggregating 357,136 RSF of recently acquired tech R&D space in our Texas market

that was renewed with rental rate changes of (33.6)% and (4.8)% (cash basis). These spaces were originally targeted for a future change in use at acquisition, but we

instead renewed them with a lower capital investment while we continue to evaluate options to convert these spaces in the future, subject to market conditions. Excluding

this lease, rental rate changes for renewed/re-leased space were 13.0% and 2.3% (cash basis) for three months ended September 30, 2024. Rental rate changes may

experience volatility from quarter to quarter based on the volume and mix of leases executed. Refer to “Projected results” in Item 2 for rental rate changes expected from

leases executed for the year ending December 31, 2024.

(3) Includes tenant improvements and leasing commissions related to a 10.5-year extension of a recently acquired lease aggregating 85,019 RSF in our Fenway submarket

to an investment-grade rated academic institution. Excluding this lease, tenant improvements and leasing commissions per RSF for the three and nine months ended

September 30, 2024 were $33.16 and $28.85, respectively, which are consistent with the five-year quarterly average of $32.17 per RSF.

(4) Refer to “New Class A/A+ development and redevelopment properties: summary of pipeline” in Item 2 for additional information, including total project costs.

(5) Includes the five-year extension of 171,102 RSF at our 4155 Campus Point Court property in San Diego, a fully leased development project expected to deliver during the

fourth quarter of 2024.

54

Summary of contractual lease expirations

The following table summarizes the contractual lease expirations at our properties as of September 30, 2024:

Year RSF Percentage of Occupied RSF Annual Rental Revenue (per RSF)(1) Percentage of Annual Rental Revenue
2024 (2) 518,665 1.4% $69.19 1.7%
2025 3,785,573 10.0% $49.64 8.8%
2026 2,714,170 7.1% $53.21 6.7%
2027 3,242,737 8.5% $51.87 7.9%
2028 4,332,150 11.4% $51.78 10.5%
2029 2,437,921 6.4% $51.25 5.8%
2030 3,135,445 8.3% $43.25 6.3%
2031 3,425,338 9.0% $55.11 8.8%
2032 1,093,311 2.9% $59.53 3.0%
2033 2,772,455 7.3% $50.81 6.6%
Thereafter 10,541,840 27.7% $68.66 33.9%

Contractual lease expirations at properties classified as held for sale as of September 30, 2024 are excluded from the information on this page.

(1) Represents amounts in effect as of September 30, 2024.

(2) Excludes month-to-month leases aggregating 355,698 RSF as of September 30, 2024.

55

The following tables present our lease expirations by market for the remainder of 2024 and for 2025 as of September 30,

2024:

Market 2024 Contractual Lease Expirations (in RSF) Leased Negotiating/ Anticipating Targeted for Future Development/Redevelopment(1) Remaining Expiring Leases Committed Near-Term/ Priority Anticipated Future Total(2) Annual Rental Revenue (per RSF)(3)
Greater Boston 73,614 21,621 — 104,500 80,788 (4) 280,523 $86.07
San Francisco Bay Area 12,847 13,943 107,250 — 14,682 148,722 49.58
San Diego 27,119 — — — 17,408 44,527 55.30
Seattle — — — — 3,652 3,652 N/A
Maryland — — — — 182 182 N/A
Research Triangle 10,478 — — — 8,202 18,680 28.31
New York City — — — — 9,058 9,058 109.57
Texas — — — — — — —
Canada 13,321 — — — — 13,321 26.54
Non-cluster/other markets — — — — — — —
Total 137,379 35,564 107,250 104,500 133,972 518,665 $69.19
Percentage of expiring leases 26% 7% 21% 20% 26% 100%
2025 Contractual Lease Expirations (in RSF) Annual Rental Revenue (per RSF)(3)
Market Leased Negotiating/ Anticipating Targeted for Future Development/ Redevelopment(1) Remaining Expiring Leases(5) Total
Greater Boston 172,446 145,715 25,312 659,355 (4) 1,002,828 $76.13
San Francisco Bay Area 72,162 247,827 — 547,092 867,081 51.33
San Diego 83,546 — 269,048 260,627 613,221 22.98
Seattle — — — 196,419 196,419 25.10
Maryland 35,055 6,926 — 151,958 193,939 27.51
Research Triangle — — — 306,916 306,916 51.16
New York City — 13,273 — 54,966 68,239 105.86
Texas — — 198,972 247,246 446,218 40.09
Canada — — — 88,412 88,412 20.28
Non-cluster/other markets — — — 2,300 2,300 40.17
Total 363,209 413,741 493,332 2,515,291 3,785,573 $49.64
Percentage of expiring leases 10% 11% 13% 66% 100%

Contractual lease expirations at properties classified as held for sale as of September 30, 2024 are excluded from the information on this page.

(1) Primarily represents assets that were recently acquired for future development and redevelopment opportunities, for which we expect, subject to market conditions and

leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development. As of September 30, 2024,

annual rental revenue from these leases expiring in 2024, including 226,144 RSF of month-to-month leases in our University Town Center submarket primarily related to

space being temporarily held over by an expiring tenant, and 2025 is $20.9 million and $17.5 million, respectively. The weighted-average expiration date of these leases

expiring in 2024 and 2025 is October 20, 2024 and January 10, 2025, respectively. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2

for additional details, including development and redevelopment square feet currently included in rental properties.

(2) Excludes month-to-month leases aggregating 355,698 RSF as of September 30, 2024. Refer to “Leasing Activity” in Item 2 for additional details.

(3) Represents amounts in effect as of September 30, 2024.

(4) Includes 41,908 RSF and 210,868 RSF expiring in 2024 and 2025, respectively, related to properties that are under executed letters of intent and/or purchase and sale

agreements to sell. Approximately 95% of the 2025 remaining expiring leases in Greater Boston are located in our Cambridge/Inner Suburbs submarket. Refer to

footnote 5 for additional details.

(5) Includes 768,080 RSF in four submarkets with a weighted-average expiration date of January 21, 2025 and annual rental revenue aggregating approximately

$47 million, with our share of this annual rental revenue aggregating $35 million, comprising the following: (i) existing laboratory spaces for which we are evaluating

options to re-lease or reposition from single tenancy to multi-tenancy that will remain in our same property pool at Alexandria Technology Square® in our Cambridge

submarket for 182,054 RSF and at 409 Illinois Street, where we have an ownership interest of 25.0%, in our Mission Bay submarket for 234,249 RSF (we are in early

discussions with a tenant to lease approximately 50% of this space); and (ii) non-laboratory space for which we are evaluating options to re-lease generally in their

current condition, reposition, or, subject to market conditions, may undergo a conversion through redevelopment in our Austin submarket for 247,246 RSF and in our

Research Triangle market for 104,531 RSF. Should we commence redevelopment efforts, these properties would be placed into our active pipeline and removed from

our same property pool; otherwise, they would remain in our same property pool. We expect downtime on the 768,080 RSF to range from 12 to 24 months on a

weighted-average basis.

56

Top 20 tenants

92% of Top 20 Tenant Annual Rental Revenue Is From Investment-Grade

or Publicly Traded Large Cap Tenants(1)

Our properties are leased to a high-quality and diverse group of tenants, with no individual tenant accounting for more than 5.8%

of our annual rental revenue in effect as of September 30, 2024. The following table sets forth information regarding leases with our 20

largest tenants in North America based upon annual rental revenue in effect as of September 30, 2024 (dollars in thousands, except

average market cap amounts):

Tenant Remaining Lease Term(1) (in Years) Aggregate RSF Moody’s Annual Rental Revenue(1) S&P Percentage of Annual Rental Revenue (1) Investment-Grade Credit Ratings Average Market Cap (in billions)
1 Moderna, Inc. 12.6 1,385,678 $127,387 5.8% — — $38.6
2 Eli Lilly and Company 8.2 1,166,754 94,814 4.3 A1 A+ $712.4
3 Bristol-Myers Squibb Company 6.4 999,379 76,363 3.5 A2 A $99.1
4 Takeda Pharmaceutical Company Limited 10.7 549,759 47,899 2.2 Baa1 BBB+ $44.5
5 Roche 6.7 770,279 47,104 2.2 Aa2 AA $227.8
6 Illumina, Inc. 7.4 857,967 35,362 1.6 Baa3 BBB $19.7
7 Alphabet Inc. 3.1 625,015 34,899 1.6 Aa2 AA+ $1,916.3
8 2seventy bio, Inc.(2) 8.9 312,805 33,543 1.5 — — $0.2
9 Novartis AG 3.8 450,664 30,969 1.4 Aa3 AA- $231.8
10 United States Government 5.9 429,359 28,593 1.3 Aaa AA+ $—
11 Cloud Software Group, Inc. 2.4 (3) 292,013 28,537 1.3 — — $—
12 Uber Technologies, Inc. 58.0 (4) 1,009,188 27,776 1.3 Baa2 BBB- $137.1
13 AstraZeneca PLC 5.1 450,848 27,156 1.2 A2 A+ $222.8
14 Harvard University 7.2 343,858 27,084 1.2 Aaa AAA $—
15 The Regents of the University of California 6.6 372,647 23,670 1.1 Aa2 AA $—
16 Sanofi 6.3 267,278 21,444 1.0 A1 AA $126.6
17 Merck & Co., Inc. 8.8 337,703 21,401 1.0 A1 A+ $300.8
18 Amgen Inc. 8.3 428,227 21,314 1.0 Baa1 BBB+ $159.2
19 New York University 7.4 218,983 21,056 1.0 Aa2 AA- $—
20 Massachusetts Institute of Technology 4.7 246,725 20,527 0.9 Aaa AAA $—
Total/weighted-average 9.5 (4) 11,515,129 $796,898 36.4%

Annual rental revenue and RSF include 100% of each property managed by us in North America. Refer to “Annual rental revenue” and “Investment-grade or publicly traded large

cap tenants” under “Definitions and reconciliations” in Item 2 for additional details, including our methodologies of calculating annual rental revenue from unconsolidated real

estate joint ventures and average market capitalization, respectively.

(1) Based on annual rental revenue in effect as of September 30, 2024.

(2) As of June 30, 2024, 2seventy bio, Inc. held $201.9 million of cash, cash equivalents, and marketable securities. In March 2024, Regeneron Pharmaceuticals, Inc., a

publicly traded biotechnology company with investment-grade credit ratings of Baa1 and BBB+ assigned by Moody’s and S&P, respectively, entered into a sublease for

approximately 195,000 RSF, or 62.8% of our annual rental revenue generated from 2seventy bio as of September 30, 2024. Additionally, 90.2% of the annual rental

revenue generated by 2seventy bio is guaranteed by another related public biotechnology company.

(3) Consists of one lease at a property acquired in 2022 with future development and redevelopment opportunities. This lease with Cloud Software Group, Inc. (formerly known

as TIBCO Software, Inc.) was in place when we acquired the property.

(4) Includes (i) ground leases for land at 1455 and 1515 Third Street (two buildings aggregating 422,980 RSF) and (ii) leases at 1655 and 1725 Third Street (two buildings

aggregating 586,208 RSF) in our Mission Bay submarket owned by our unconsolidated real estate joint venture in which we have an ownership interest of 10%. Annual

rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue from our unconsolidated real

estate joint ventures. Excluding these ground leases, the weighted-average remaining lease term for our top 20 tenants was 7.8 years as of September 30, 2024.

57

Locations of properties

The locations of our properties are diversified among a number of Class A/A+ assets strategically clustered in mega campuses

in AAA life science innovation cluster markets. The following table sets forth the total RSF, number of properties, and annual rental

revenue in effect as of September 30, 2024 in each of our markets in North America (dollars in thousands, except per RSF amounts):

Market RSF Operating Development Redevelopment Total % of Total Number of Properties Total Annual Rental Revenue % of Total Per RSF
Greater Boston 10,352,695 764,036 1,762,974 (1) 12,879,705 28% 72 $833,562 38% $85.09
San Francisco Bay Area 7,784,590 498,142 259,689 8,542,421 18 65 432,102 20 63.54
San Diego 7,673,315 1,186,104 — 8,859,419 19 87 330,596 15 44.90
Seattle 3,108,593 227,577 34,306 3,370,476 7 45 137,044 6 47.78
Maryland 3,819,512 29,890 — 3,849,402 8 50 145,847 7 40.12
Research Triangle 3,770,927 — — 3,770,927 8 38 116,318 5 31.64
New York City 921,686 — — 921,686 2 4 72,439 3 92.37
Texas 1,845,159 — 73,298 1,918,457 4 15 54,958 3 31.19
Canada 887,737 — 139,311 1,027,048 2 11 19,790 1 23.33
Non-cluster/other markets 347,806 — — 347,806 1 10 14,623 1 57.76
Properties held for sale 1,261,387 — — 1,261,387 3 9 26,796 1 N/A
North America 41,773,407 2,705,749 2,269,578 46,748,734 100% 406 $2,184,075 100% $57.09
4,975,327

(1) Primarily includes our active redevelopment projects aggregating 735,744 RSF at 40, 50, and 60 Sylvan Road and 840 Winter Street located on the Alexandria Center®

for Life Science – Waltham mega campus. This mega campus project is expected to capture demand in our Route 128 submarket.

Summary of occupancy percentages in North America

The following table sets forth the occupancy percentages for our operating properties and our operating and redevelopment

properties in each of our North America markets, excluding properties held for sale, as of the following dates:

Market Operating Properties 9/30/24 6/30/24 9/30/23 Operating and Redevelopment Properties 9/30/24 6/30/24 9/30/23
Greater Boston 94.6% 94.2% 93.2% 80.9% 81.7% 83.3%
San Francisco Bay Area 94.1 94.0 95.3 91.1 90.7 91.9
San Diego 96.0 95.1 90.9 96.0 95.1 90.9
Seattle 92.3 (1) 94.7 95.1 91.3 93.7 90.3
Maryland 96.2 96.5 96.6 96.2 96.5 96.6
Research Triangle 97.5 97.4 96.9 97.5 97.4 96.9
New York City 85.1 (2) 85.1 89.4 85.1 85.1 89.4
Texas 95.5 95.5 95.1 91.8 91.8 91.5
Subtotal 94.9 94.7 93.9 90.0 90.2 89.9
Canada 95.5 94.9 88.9 82.6 82.5 75.7
Non-cluster/other markets 72.8 75.6 80.5 72.8 75.6 80.5
North America 94.7% 94.6% 93.7% 89.7% 89.9% 89.4%

(1) Decline in occupancy relates to the expiration of an acquired non-laboratory lease aggregating 87,273 RSF at one property in our Bothell submarket that is expected to

be converted to laboratory space subject to market conditions and leasing.

(2) The Alexandria Center® for Life Science – New York City mega campus is 95.3% occupied as of September 30, 2024. Occupancy percentage in our New York City

market reflects vacancy at the Alexandria Center® for Life Science – Long Island City property, which was 42.8% occupied as of September 30, 2024.

58

Investments in real estate

A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new

Class A/A+ properties, and property enhancements identified during the underwriting of certain acquired properties, located in

collaborative mega campuses in AAA life science innovation clusters. These projects are focused on providing high-quality, generic, and

reusable spaces that meet the real estate requirements of a wide range of tenants. Upon completion, each development and

redevelopment project is expected to generate increases in rental income, net operating income, and cash flows. Our development and

redevelopment projects are generally in locations that are highly desirable to high-quality entities, which we believe results in higher

occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. Our pre-construction

activities are undertaken in order to prepare the property for its intended use and include entitlements, permitting, design, site work, and

other activities preceding commencement of construction of aboveground building improvements.

Our investments in real estate consisted of the following as of September 30, 2024 (dollars in thousands):

Square footage Operating Development and Redevelopment Active and Near-Term Construction Under Construction 55% Leased/ Negotiating Committed Near Term 51% Leased/ Negotiating(1) Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated Future Subtotal Total
Operating 40,512,020 — — — — — 40,512,020
New Class A/A+ development and redevelopment properties — 4,975,327 492,570 2,163,784 27,582,766 35,214,447 35,214,447
Future development and redevelopment square feet currently included in rental properties(2) — — (159,884) (258,596) (2,957,559) (3,376,039) (3,376,039)
Total square footage, excluding properties held for sale 40,512,020 4,975,327 332,686 1,905,188 24,625,207 31,838,408 72,350,428
Properties held for sale 1,261,387 — — — — — 1,261,387
Total square footage 41,773,407 4,975,327 332,686 1,905,188 24,625,207 31,838,408 73,611,815 (3)
Investments in real estate
Gross book value as of September 30, 2024(4) $29,235,994 $4,335,573 $69,521 $578,694 $4,356,637 $9,340,425 $38,576,419

(1) Represents one committed near-term project expected to commence construction during the next two years after September 30, 2024.

(2) Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional details, including future development and redevelopment square feet

currently included in rental properties.

(3) We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending December 31, 2024 with dispositions primarily

focused on sales of properties and land parcels not integral to our mega campus strategy.

(4) Balances exclude accumulated depreciation and our share of the cost basis associated with our properties held by our unconsolidated real estate joint ventures, which is

classified as investments in unconsolidated real estate joint ventures in our consolidated balance sheets.

59

Acquisitions

Our real estate asset acquisitions during the nine months ended September 30, 2024 and pending as of the date of this report consisted of the following (dollars in thousands):

Property Completed during the nine months ended September 30, 2024: Submarket/Market Date of Purchase Future Development(1) Number of Properties Operating With Future Development/ Redevelopment(1) Operating Occupancy Purchase Price Square Footage
285, 299, 307, and 345 Dorchester Avenue (60% interest in consolidated JV)(2) Seaport Innovation District/ Greater Boston 1/30/24 — N/A 1,040,000 — $155,321
Other 46,490
201,811
Completed in October 2024:
428 Westlake Avenue North Lake Union/Seattle 10/1/24 1 100% — 88,514 47,600
$249,411
2024 guidance range for acquisitions $250,000 – $750,000

(1) We expect to provide total estimated costs and related yields for development and significant redevelopment projects in the future, subsequent to the commencement of construction.

(2) Refer to Note 4 – “Consolidated and unconsolidated real estate joint ventures” to our unaudited consolidated financial statements in Item 1 for additional details.

60

Dispositions

Our completed dispositions of real estate assets during the nine months ended September 30, 2024 and pending as of the date of this report consisted of the following (dollars in

thousands):

Property Submarket/Market Completed during the six months ended June 30, 2024: Dispositions of 100% interest in properties not integral to our mega campus strategy Date of Sale Interest Sold RSF Capitalization Rate Capitalization Rate (Cash Basis) Sales Price Sales Price per RSF
99 A Street(1) Seaport Innovation District/ Greater Boston 3/8/24 100% 235,000 N/A N/A $13,350 N/A
Other 3,863
17,213
Completed during the three months ended September 30, 2024:
Sale to longstanding tenant
1165 Eastlake Avenue East Lake Union/Seattle 9/12/24 100% 100,086 4.7% 4.9% 149,985 (2) $1,499
Dispositions of properties not integral to our mega campus strategy
219 East 42nd Street New York City/New York City 7/9/24 100% 349,947 N/A N/A 60,000 (3) N/A
Other 11,511
221,496 (4)
Dispositions completed during the nine months ended September 30, 2024 238,709
Completed in October 2024:
Dispositions of properties not integral to our mega campus strategy
14225 Newbrook Drive Northern Virginia/Maryland 10/15/24 100% 248,186 7.6% 7.4% 80,500 (5) $324
319,209
Pending dispositions for the fourth quarter of 2024 subsequent to the date of this report:
Subject to non-refundable deposits
Sale to longstanding tenant Greater Boston 4Q24 100% 8.5% 6.3% 369,439 (6)
Other 207,713
577,152
Subject to executed letters of intent and/or purchase and sale agreements 602,500 (6)
1,179,652 (7)
$1,498,861
2024 guidance range for dispositions and common equity $1,050,000 – $2,050,000

(1) We completed the sale during the three months ended March 31, 2024 and recognized no gain or loss. Refer to Note 3 – “Investments in real estate” to our unaudited consolidated financial statements in Item 1 for additional information.

(2) Upon completion of the sale, we recognized a gain on sale of real estate aggregating $21.5 million during the three months ended September 30, 2024.

(3) The property was leased to a single tenant with a July 2024 lease expiration and had annual net operating income of $18.6 million based on three months ended June 30, 2024 annualized. This property was previously considered to be a

potential development project upon expiration of the in-place non-laboratory space lease.

(4) Dispositions completed during the three months ended September 30, 2024 had annual net operating income of $26.5 million (based on three months ended June 30, 2024 annualized) with a weighted-average disposition date of July 28,

2024 (weighted by net operating income for the three months ended June 30, 2024 annualized).

(5) Demonstrating the long-term enduring value of our laboratory facilities, Alexandria successfully operated our only asset in the Northern Virginia submarket from its acquisition in 1997 (prior to our IPO) through its sale in October 2024. Upon

completion of the sale, we recognized a gain on sale of real estate aggregating $37.1 million.

(6) Refer to Note 16 – “Subsequent events” to our unaudited consolidated financial statements in Item 1 for additional information.

(7) Pending dispositions subsequent to the date of this report have estimated annual net operating income of approximately $95.8 million (based on three months ended September 30, 2024 annualized) with a weighted-average estimated

disposition date of December 5, 2024 (weighted by net operating income for the three months ended September 30, 2024 annualized). Approximately half of our pending dispositions are non-core stabilized stand-alone properties with

weighted-average capitalization rates of 8.5% and 7.0% (cash basis), and the remaining half are land and non-stabilized properties that have vacancy or significant near-term lease expirations that will require capital to re-tenant, including

one building with approximately 72% of non-laboratory space.

61

New Class A/A+ development and redevelopment properties

ALEXANDRIA’S FUTURE GROWTH IN

ANNUAL NET OPERATING INCOME FROM

DEVELOPMENT AND REDEVELOPMENT DELIVERIES

$510 MILLION

(1)

Placed Into Service

Expected to Be Placed Into Service

(2)

YTD 3Q24 3Q24
$63M $21M
945,118 RSF 316,691 RSF
100% Leased

(3)

4Q24–4Q25 1Q26–1Q28
$158M $352M
Aggregating 5.5M RSF
55% Leased/Negotiating

Refer to “Net operating income” under “Definitions and reconciliations” in Item 2 for additional details, including its reconciliation from the most directly comparable financial measures presented in accordance with GAAP.

(1) Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 4Q24 through 1Q28 is projected to be $407 million.

(2) Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed near-term project expected to commence construction in the next two

years.

(3) Includes (i) 1.0 million RSF that is expected to stabilize through 2025 and is 92% leased/negotiating and (ii) expected partial deliveries through 4Q25 from projects expected to stabilize in 2026 and beyond. Refer to the initial and stabilized

occupancy years under “New Class A/A+ development and redevelopment properties: current projects” in Item 2 for additional details.

62

New Class A/A+ development and redevelopment properties: recent deliveries

500 North Beacon Street and 4 Kingsbury Avenue(1) 651 Gateway Boulevard 1150 Eastlake Avenue East
Greater Boston/ Cambridge/Inner Suburbs San Francisco Bay Area/ South San Francisco Seattle/Lake Union
138,537 RSF 67,017 RSF 311,631 RSF
100% Occupancy 100% Occupancy 100% Occupancy
9810 Darnestown Road 9820 Darnestown Road 9808 Medical Center Drive
Maryland/Rockville Maryland/Rockville Maryland/Rockville
195,435 RSF 250,000 RSF 65,171 RSF
100% Occupancy 100% Occupancy 100% Occupancy

(1) Image represents 500 North Beacon Street on The Arsenal on the Charles mega campus.

63

New Class A/A+ development and redevelopment properties: recent deliveries (continued)

The following table presents development and redevelopment of new Class A/A+ projects placed into service during the nine months ended September 30, 2024 (dollars in

thousands):

Incremental Annual Net Operating Income Generated From YTD 3Q24 Deliveries

Aggregated $63 Million, Including $21 Million in 3Q24

Property/Market/Submarket Development projects 3Q24 Delivery Date(1) Prior to 1/1/24 Our Ownership Interest 1Q24 RSF Placed in Service 2Q24 3Q24 RSF Total Investment Occupancy Percentage(2) Initial Stabilized Total Project Initial Stabilized (Cash Basis) Unlevered Yields
99 Coolidge Avenue/Greater Boston/Cambridge/ Inner Suburbs N/A 75.0% 43,568 72,846 — — 116,414 100% 320,809 $468,000 7.1% 7.0%
500 North Beacon Street and 4 Kingsbury Avenue/ Greater Boston/Cambridge/Inner Suburbs N/A 100% — 100,624 37,913 — 138,537 100% 248,018 427,000 6.2 5.5
1150 Eastlake Avenue East/Seattle/Lake Union 7/16/24 100% 278,282 — 2,079 31,270 311,631 100% 311,631 442,000 6.6 6.7
9810 Darnestown Road/Maryland/Rockville N/A 100% — — 195,435 — 195,435 100% 195,435 135,000 7.1 6.2
9820 Darnestown Road/Maryland/Rockville 8/21/24 100% — — — 250,000 250,000 100% 250,000 177,000 8.7 5.6
9808 Medical Center Drive/Maryland/Rockville 7/25/24 100% 26,460 — 25,655 13,056 65,171 100% 95,061 115,000 5.4 5.4
Redevelopment projects
651 Gateway Boulevard/San Francisco Bay Area/ South San Francisco 7/12/24 50.0% — 44,652 — 22,365 67,017 100% 326,706 487,000 5.0 5.1
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell N/A 100% 65,086 115,598 — — 180,684 100% 460,934 229,000 6.3 6.2
Canada N/A 100% 44,862 9,725 23,900 — 78,487 100% 250,790 113,000 6.4 6.3
Weighted average/total 8/11/24 458,258 343,445 284,982 316,691 1,403,376 2,459,384 $2,593,000 6.4% 6.0%

(1) Represents the average delivery date for deliveries that occurred during the three months ended September 30, 2024, weighted by annual rental revenue.

(2) Occupancy relates to total operating RSF placed in service as of the most recent delivery.

64

New Class A/A+ development and redevelopment properties: current projects

99 Coolidge Avenue 500 North Beacon Street and 4 Kingsbury Avenue(1) 311 Arsenal Street 201 Brookline Avenue 401 Park Drive
Greater Boston/ Cambridge/Inner Suburbs Greater Boston/ Cambridge/Inner Suburbs Greater Boston/ Cambridge/Inner Suburbs Greater Boston/Fenway Greater Boston/Fenway
204,395 RSF 109,481 RSF 308,446 RSF 58,149 RSF 159,959 RSF
40% Leased/Negotiating 92% Leased 21% Leased 100% Leased 14% Leased
421 Park Drive 40, 50, and 60 Sylvan Road(2) 840 Winter Street 1450 Owens Street(3) 651 Gateway Boulevard
Greater Boston/Fenway Greater Boston/Route 128 Greater Boston/Route 128 San Francisco Bay Area/ Mission Bay San Francisco Bay Area/ South San Francisco
392,011 RSF 596,064 RSF 139,680 RSF 212,796 RSF 259,689 RSF
13% Leased 31% Leased 100% Leased —% Leased/Negotiating 25% Leased/Negotiating

(1) Image represents 500 North Beacon Street on The Arsenal on the Charles mega campus.

(2) Image represents 60 Sylvan Road on the Alexandria Center® for Life Science – Waltham mega campus. The project is expected to capture demand in our Route 128 submarket.

(3) Image represents a multi-tenant project expanding our existing Alexandria Center® for Science and Technology – Mission Bay mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an

ownership interest of 75%, after which it will contribute its respective share of additional capital. We are in negotiations with a biomedical institution for the sale of a 50% condominium interest in this property.

65

New Class A/A+ development and redevelopment properties: current projects (continued)

230 Harriet Tubman Way 10935, 10945, and 10955 Alexandria Way(1) 4135 Campus Point Court 4155 Campus Point Court
San Francisco Bay Area/ South San Francisco San Diego/Torrey Pines San Diego/ University Town Center San Diego/ University Town Center
285,346 RSF 334,996 RSF 426,927 RSF 171,102 RSF
100% Leased 100% Leased 100% Leased 100% Leased
10075 Barnes Canyon Road 701 Dexter Avenue North(2) Alexandria Center® for Advanced Technologies – Monte Villa Parkway(3) 9808 Medical Center Drive 8800 Technology Forest Place
San Diego/Sorrento Mesa Seattle/Lake Union Seattle/Bothell Maryland/Rockville Texas/Greater Houston
253,079 RSF 227,577 RSF 34,306 RSF 29,890 RSF 73,298 RSF
70% Leased —% Leased/Negotiating 98% Leased 76% Leased/Negotiating 41% Leased

(1) Image represents 10955 Alexandria Way on the One Alexandria Square mega campus.

(2) We initially started this project due to strong demand from neighboring tenants but strategically paused in the first quarter of 2023. We have resumed construction activities at this project in order to maintain our existing entitlements and

permits. We have interest from various prospective tenants, including from multinational pharmaceutical companies. Beyond this purpose-built life science asset, there is no competitive supply expected to be delivered in 2025 or 2026 in

our Lake Union submarket. As of September 30, 2024, we are 95.3% occupied in our Lake Union submarket.

(3) Image represents 3755 Monte Villa Parkway.

66

New Class A/A+ development and redevelopment properties: current projects (continued)

The following tables set forth a summary of our new Class A/A+ development and redevelopment properties under construction and pre-leased/negotiating near-term projects as of

September 30, 2024 (dollars in thousands):

Property/Market/Submarket Dev/Redev Under construction 2024 and 2025 stabilization In Service Square Footage CIP Total Percentage Leased Leased/ Negotiating Occupancy(1) Initial Stabilized
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs Dev 138,537 109,481 248,018 92% 92% 1Q24 2025
201 Brookline Avenue/Greater Boston/Fenway Dev 451,967 58,149 510,116 100 100 3Q22 4Q24
840 Winter Street/Greater Boston/Route 128 Redev 28,534 139,680 168,214 100 100 4Q24 2025
230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco Dev — 285,346 285,346 100 100 1Q25 1Q25
4155 Campus Point Court/San Diego/University Town Center Dev — 171,102 171,102 100 100 4Q24 4Q24
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell Redev 426,628 34,306 460,934 98 98 1Q23 4Q24
9808 Medical Center Drive/Maryland/Rockville Dev 65,171 29,890 95,061 69 76 3Q23 4Q24
8800 Technology Forest Place/Texas/Greater Houston Redev 50,094 73,298 123,392 41 41 2Q23 2025
Canada Redev 111,479 139,311 250,790 73 73 3Q23 2025
1,272,410 1,040,563 2,312,973 91 92
2026 and beyond stabilization
One Hampshire Street/Greater Boston/Cambridge Redev — 104,956 104,956 — — 2027 2028
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs Redev 82,216 (2) 308,446 390,662 21 21 2027 2027
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs Dev 116,414 204,395 320,809 40 40 4Q23 2026
401 Park Drive/Greater Boston/Fenway Redev — 159,959 159,959 14 14 2024 2026
421 Park Drive/Greater Boston/Fenway Dev — 392,011 392,011 13 13 2026 2027
40, 50, and 60 Sylvan Road/Greater Boston/Route 128 Redev — 596,064 596,064 31 31 2025 2027
Other/Greater Boston Redev — 453,869 453,869 — — (3) 2027 2027
1450 Owens Street/San Francisco Bay Area/Mission Bay Dev — 212,796 212,796 — — (4) 2025 2026
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco Redev 67,017 259,689 326,706 21 25 1Q24 2026
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines Dev — 334,996 334,996 100 100 4Q24 2026
4135 Campus Point Court/San Diego/University Town Center Dev — 426,927 426,927 100 100 2026 2026
10075 Barnes Canyon Road/San Diego/Sorrento Mesa Dev — 253,079 253,079 70 70 2025 2026
701 Dexter Avenue North/Seattle/Lake Union Dev — 227,577 227,577 — — (5) 2026 2027
265,647 3,934,764 4,200,411 35 36
1,538,057 4,975,327 6,513,384 55 55
Committed near-term project expected to commence construction in the next two years
4165 Campus Point Court/San Diego/University Town Center Dev — 492,570 492,570 — 51
Total 1,538,057 5,467,897 7,005,954 51% 55%
(1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time. (2)We expect to redevelop an additional 25,312 RSF of space occupied as of September 30, 2024 into laboratory space upon expiration of the existing leases through the second half of 2025. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information. (3)Represents a project focused on demand from our existing tenants in our adjacent properties/campuses that will address demand from other non-Alexandria properties/campuses. (4)Represents a multi-tenant project expanding our existing mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an ownership interest of 75%, after which it will contribute its respective share of additional capital. We are in negotiations with a biomedical institution for the sale of a 50% condominium interest in this property. (5)We initially started this project due to strong demand from neighboring tenants but strategically paused in the first quarter of 2023. We have resumed construction activities at this project in order to maintain our existing entitlements and permits. We have interest from various prospective tenants, including from multinational pharmaceutical companies. Beyond this purpose-built life science asset, there is no competitive supply expected to be delivered in 2025 or 2026 in our Lake Union submarket. As of September 30, 2024, we are 95.3% occupied in our Lake Union submarket.

67

New Class A/A+ development and redevelopment properties: current projects (continued)

Property/Market/Submarket Under construction 2024 and 2025 stabilization Our Ownership Interest In Service At 100% CIP Cost to Complete Unlevered Yields Total at Completion Initial Stabilized Initial Stabilized (Cash Basis)
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs 100% $284,645 $115,506 $26,849 $427,000 6.2% 5.5%
201 Brookline Avenue/Greater Boston/Fenway 99.0% 665,877 91,610 17,513 775,000 7.2% 6.5%
840 Winter Street/Greater Boston/Route 128 100% 13,653 187,366 35,981 237,000 7.6% 6.5%
230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco 47.9% — 350,231 159,769 510,000 7.4% 6.4%
4155 Campus Point Court/San Diego/University Town Center 55.0% — 140,300 43,700 184,000 8.0% 6.4%
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell 100% 193,823 11,977 23,200 229,000 6.3% 6.2%
9808 Medical Center Drive/Maryland/Rockville 100% 79,320 33,018 2,662 115,000 5.4% 5.4%
8800 Technology Forest Place/Texas/Greater Houston 100% 57,315 46,202 8,483 112,000 6.3% 6.0%
Canada 100% 50,219 50,044 12,737 113,000 6.4% 6.3%
1,344,852 1,026,254
2026 and beyond stabilization(1)
One Hampshire Street/Greater Boston/Cambridge 100% — 161,328 TBD
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs 100% 60,625 233,563
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs 75.0% 136,527 192,432 139,041 468,000 7.1% 7.0%
401 Park Drive/Greater Boston/Fenway 100% — 194,421 TBD
421 Park Drive/Greater Boston/Fenway 99.7% — 422,278
40, 50, and 60 Sylvan Road/Greater Boston/Route 128 100% — 437,356
Other/Greater Boston 100% — 148,804
1450 Owens Street/San Francisco Bay Area/Mission Bay 25.4% — 234,665
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco 50.0% 87,357 256,413 143,230 487,000 5.0% 5.1%
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines 100% — 359,926 143,074 503,000 6.2% 5.8%
4135 Campus Point Court/San Diego/University Town Center 55.0% — 292,913 231,087 524,000 6.6% 6.2%
10075 Barnes Canyon Road/San Diego/Sorrento Mesa 50.0% — 168,582 152,418 321,000 5.5% 5.7%
701 Dexter Avenue North/Seattle/Lake Union 100% — 206,638 TBD
284,509 3,309,319
1,629,361 4,335,573
Committed near-term project expected to commence construction in the next two years
4165 Campus Point Court/San Diego/University Town Center 55.0% — 69,521 TBD
Total $1,629,361 $4,405,094 $3,780,000 (2) $9,820,000 (2)
Our share of investment(2)(3) $1,550,000 $3,570,000 $3,030,000 $8,150,000
Refer to “Initial stabilized yield (unlevered)” under “Definitions and reconciliations” in Item 2 for additional information. (1)We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2026 and beyond over the next several quarters. (2)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD. (3)Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects.

68

New Class A/A+ development and redevelopment properties: summary of pipeline

69% of Our Total Development and Redevelopment Pipeline RSF Is Within Our Mega Campuses

The following table summarizes the key information for all our development and redevelopment projects in North America as of September 30, 2024 (dollars in thousands):

Market Property/Submarket Greater Boston Our Ownership Interest Under Construction Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated Future Total(1)
Mega Campus: Alexandria Center® at One Kendall Square/ Cambridge 100% $161,328 104,956 — — — 104,956
One Hampshire Street
Mega Campus: The Arsenal on the Charles/Cambridge/Inner Suburbs 100% 360,538 417,927 — 25,312 34,157 477,396
311 Arsenal Street, 500 North Beacon Street, and 4 Kingsbury Avenue
Mega Campus: 480 Arsenal Way and 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue/Cambridge/Inner Suburbs (2) 279,763 204,395 — — 902,000 1,106,395
446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue
Mega Campus: Alexandria Center® for Life Science – Fenway/ Fenway (3) 708,309 610,119 — — — 610,119
201 Brookline Avenue and 401 and 421 Park Drive
Mega Campus: Alexandria Center® for Life Science – Waltham/ Route 128 100% 687,346 735,744 — — 515,000 1,250,744
40, 50, and 60 Sylvan Road, 35 Gatehouse Drive, and 840 Winter Street
Mega Campus: Alexandria Center® at Kendall Square/ Cambridge 100% 126,688 — — — 216,455 216,455
100 Edwin H. Land Boulevard
Mega Campus: Alexandria Technology Square®/Cambridge 100% 7,881 — — — 100,000 100,000
Mega Campus: 285, 299, 307, and 345 Dorchester Avenue/ Seaport Innovation District 60.0% 286,300 — — — 1,040,000 1,040,000
10 Necco Street/Seaport Innovation District 100% 105,111 — — — 175,000 175,000
Mega Campus: One Moderna Way/Route 128 100% 26,052 — — — 1,085,000 1,085,000
215 Presidential Way/Route 128 100% 6,816 — — — 112,000 112,000
Other development and redevelopment projects (4) 310,381 453,869 — — 1,323,541 1,777,410
$3,066,513 2,527,010 — 25,312 5,503,153 8,055,475
Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We have a 75.0% interest in 99 Coolidge Avenue aggregating 204,395 RSF and 100.0% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF. (3)We have a 99.0% interest in 201 Brookline Avenue aggregating 58,149 RSF, a 100% interest in 401 Park Drive aggregating 159,959 RSF, and a 99.7% interest in 421 Park Drive aggregating 392,011 RSF. (4)Includes a property in which we own a partial interest through a real estate joint venture.

69

New Class A/A+ development and redevelopment properties: summary of pipeline (continued)

Market Property/Submarket San Francisco Bay Area Our Ownership Interest Under Construction Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated Future Total(1)
Mega Campus: Alexandria Center® for Science and Technology – Mission Bay/Mission Bay 25.4% $234,665 212,796 — — — 212,796
1450 Owens Street
Alexandria Center® for Life Science – Millbrae/South San Francisco 47.9% 510,162 285,346 — 198,188 150,213 633,747
230 Harriet Tubman Way, 201 and 231 Adrian Road, and 6 and 30 Rollins Road
Mega Campus: Alexandria Technology Center® – Gateway/ South San Francisco 50.0% 283,002 259,689 — — 291,000 550,689
651 Gateway Boulevard
Mega Campus: Alexandria Center® for Advanced Technologies – Tanforan/South San Francisco 100% 397,159 — — 150,000 1,780,000 1,930,000
1122, 1150, and 1178 El Camino Real
Mega Campus: Alexandria Center® for Advanced Technologies – South San Francisco/South San Francisco 100% 6,655 — — 107,250 90,000 197,250
211(2) and 269 East Grand Avenue
Mega Campus: Alexandria Center® for Life Science – San Carlos/Greater Stanford 100% 446,892 — — 105,000 1,392,830 1,497,830
960 Industrial Road, 987 and 1075 Commercial Street, and 888 Bransten Road
3825 and 3875 Fabian Way/Greater Stanford 100% 154,174 — — — 478,000 478,000
2100, 2200, 2300, and 2400 Geng Road/Greater Stanford 100% 36,509 — — — 240,000 240,000
901 California Avenue/Greater Stanford 100% 19,770 — — — 56,924 56,924
Mega Campus: 88 Bluxome Street/SoMa 100% 392,785 — — — 1,070,925 1,070,925
Other development and redevelopment projects 100% — — — — 25,000 25,000
$2,481,773 757,831 — 560,438 5,574,892 6,893,161
Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We own a partial interest in this property through a real estate joint venture. Refer to Note 4 – “Consolidated and unconsolidated real estate joint ventures” to our unaudited consolidated financial statements in Item 1 for additional details.

70

New Class A/A+ development and redevelopment properties: summary of pipeline (continued)

Market Property/Submarket San Diego Our Ownership Interest Under Construction Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated Future Total(1)
Mega Campus: One Alexandria Square/Torrey Pines 100% $417,621 334,996 — — 125,280 460,276
10935, 10945, and 10955 Alexandria Way and 10975 and 10995 Torreyana Road
Mega Campus: Campus Point by Alexandria/University Town Center 55.0% 671,303 598,029 492,570 — 650,000 1,740,599
10010(2), 10140(2), and 10260 Campus Point Drive and 4135, 4155, 4161, 4165, and 4275(2) Campus Point Court
Mega Campus: SD Tech by Alexandria/Sorrento Mesa 50.0% 317,172 253,079 — 250,000 243,845 746,924
9805 Scranton Road and 10065 and 10075 Barnes Canyon Road
11255 and 11355 North Torrey Pines Road/Torrey Pines 100% 150,187 — — 153,000 62,000 215,000
Costa Verde by Alexandria/University Town Center 100% 138,107 — — — 537,000 537,000
8410-8750 Genesee Avenue and 4282 Esplanade Court
Mega Campus: 5200 Illumina Way/University Town Center 51.0% 17,441 — — — 451,832 451,832
ARE Towne Centre/University Town Center 100% 19,869 — — — 230,000 230,000
9363, 9373, and 9393 Towne Centre Drive
9625 Towne Centre Drive/University Town Center 30.0% 837 — — — 100,000 100,000
Mega Campus: Sequence District by Alexandria/Sorrento Mesa 100% 46,323 — — — 1,798,915 1,798,915
6260, 6290, 6310, 6340, 6350, and 6450 Sequence Drive
Scripps Science Park by Alexandria/Sorrento Mesa 100% 120,941 — — — 598,349 598,349
10048, 10219, 10256, and 10260 Meanley Drive and 10277 Scripps Ranch Boulevard
Pacific Technology Park/Sorrento Mesa 50.0% 23,857 — — — 149,000 149,000
9444 Waples Street
4025, 4031, 4045, and 4075 Sorrento Valley Boulevard/Sorrento Valley 100% 43,641 — — — 247,000 247,000
Other development and redevelopment projects (3) 75,716 — — — 475,000 475,000
$2,043,015 1,186,104 492,570 403,000 5,668,221 7,749,895
Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We have a 100% interest in this property. (3)Includes a property in which we own a partial interest through a real estate joint venture.

71

New Class A/A+ development and redevelopment properties: summary of pipeline (continued)

Market Property/Submarket Seattle Our Ownership Interest Under Construction Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated Future Total(1)
Mega Campus: Alexandria Center® for Life Science – South Lake Union/Lake Union (2) $485,628 227,577 — 869,000 188,400 1,284,977
601 and 701 Dexter Avenue North and 800 Mercer Street
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Bothell 100% 11,977 34,306 — — — 34,306
3301 Monte Villa Parkway
830 and 1010 4th Avenue South/SoDo 100% 59,262 — — — 597,313 597,313
410 West Harrison Street/Elliott Bay 100% — — — — 91,000 91,000
Mega Campus: Alexandria Center® for Advanced Technologies – Canyon Park/Bothell 100% 17,439 — — — 230,000 230,000
21660 20th Avenue Southeast
Other development and redevelopment projects 100% 142,484 — — — 706,087 706,087
716,790 261,883 — 869,000 1,812,800 2,943,683
Maryland
Mega Campus: Alexandria Center® for Life Science – Shady Grove/Rockville 100% 54,904 29,890 — — 296,000 325,890
9808 Medical Center Drive and 9830 Darnestown Road
54,904 29,890 — — 296,000 325,890
Research Triangle
Mega Campus: Alexandria Center® for Advanced Technologies and Agtech – Research Triangle/Research Triangle 100% 103,653 — — 180,000 990,000 1,170,000
4 and 12 Davis Drive
Mega Campus: Alexandria Center® for Life Science – Durham/ Research Triangle 100% 176,524 — — — 2,210,000 2,210,000
41 Moore Drive
Mega Campus: Alexandria Center® for NextGen Medicines/ Research Triangle 100% $108,035 — — — 1,055,000 1,055,000
3029 East Cornwallis Road
Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information. (1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties. (2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the priority anticipated development project at 800 Mercer Street aggregating 869,000 RSF.

72

New Class A/A+ development and redevelopment properties: summary of pipeline (continued)

Market Property/Submarket Research Triangle (continued) Our Ownership Interest Under Construction Book Value Development and Redevelopment Active and Near-Term Construction Committed Near Term Square Footage Future Opportunities Subject to Market Conditions and Leasing Priority Anticipated Future Total(1)
Mega Campus: Alexandria Center® for Sustainable Technologies/Research Triangle 100% $53,326 — — — 750,000 750,000
120 TW Alexander Drive, 2752 East NC Highway 54, and 10 South Triangle Drive
100 Capitola Drive/Research Triangle 100% — — — — 65,965 65,965
Other development and redevelopment projects 100% 4,185 — — — 76,262 76,262
445,723 — — 180,000 5,147,227 5,327,227
New York City
Mega Campus: Alexandria Center® for Life Science – New York City/New York City 100% 165,061 — — — 550,000 (2) 550,000
165,061 — — — 550,000 550,000
Texas
Alexandria Center® for Advanced Technologies at The Woodlands/ Greater Houston 100% 49,034 73,298 — — 116,405 189,703
8800 Technology Forest Place
1001 Trinity Street and 1020 Red River Street/Austin 100% 10,177 — — 126,034 123,976 250,010
Other development and redevelopment projects 100% 136,980 — — — 1,694,000 1,694,000
196,191 73,298 — 126,034 1,934,381 2,133,713
Canada 100% 50,044 139,311 — — 371,743 511,054
Other development and redevelopment projects 100% 120,411 — — — 724,349 724,349
Total pipeline as of September 30, 2024 $9,340,425 (3) 4,975,327 492,570 2,163,784 27,582,766 35,214,447

Refer to “Mega campus” under “Definitions and reconciliations” in Item 2 for additional information.

(1) Total square footage includes 3,376,039 RSF of buildings currently in operation that we expect to demolish or redevelop and commence future construction subject to market conditions and leasing. Refer to “Investments in real estate”

under “Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.

(2) During the three months ended September 30, 2024, we filed a lawsuit against the New York City Health + Hospitals Corporation and the New York City Economic Development Corporation for fraud and breach of contract concerning our

option to ground lease a land parcel to develop a future world-class life science building within the Alexandria Center® for Life Science – New York City campus. Refer to “Legal proceedings” in Item 1 under Part II – Other Information for

additional details.

(3) Includes $4.3 billion of projects that are currently under construction and are 55% leased/negotiating. We also expect to commence construction of one committed near-term project aggregating $69.5 million, which is 51% leased/

negotiating, in the next two years after September 30, 2024.

73

Results of operations

We present a tabular comparison of items, whether gain or loss, that may facilitate a high-level understanding of our results

and provide context for the disclosures included in our annual report on Form 10-K for the year ended December 31, 2023 and our

subsequent quarterly reports on Form 10-Q. We believe that such tabular presentation promotes a better understanding for investors of

the corporate-level decisions made and activities performed that significantly affect comparison of our operating results from period to

period. We also believe that this tabular presentation will supplement for investors an understanding of our disclosures and real estate

operating results. Gains or losses on sales of real estate and impairments of assets classified as held for sale are related to corporate-

level decisions to dispose of real estate. Gains or losses on early extinguishment of debt are related to corporate-level financing

decisions focused on our capital structure strategy. Significant realized and unrealized gains or losses on non-real estate investments,

impairments of real estate and non-real estate investments, and acceleration of stock compensation expense due to the resignations of

executive officers are not related to the operating performance of our real estate assets as they result from strategic, corporate-level

non-real estate investment decisions and external market conditions. Impairments of non-real estate investments are not related to the

operating performance of our real estate as they represent the write-down of non-real estate investments when their fair values

decrease below their respective carrying values due to changes in general market or other conditions outside of our control. Significant

items, whether a gain or loss, included in the tabular disclosure for current periods are described in further detail in Item 2. Key items

included in net income attributable to Alexandria’s common stockholders for the three and nine months ended September 30, 2024 and

2023 and the related per share amounts were as follows (in millions, except per share amounts):

Three Months Ended September 30, 2024 Amount 2023 2024 Per Share – Diluted 2023 Nine Months Ended September 30, 2024 Amount 2023 2024 Per Share – Diluted 2023
Unrealized gains (losses) on non-real estate investments $2.6 $(77.2) $0.02 $(0.45) $(32.5) $(221.0) $(0.19) $(1.29)
Gain on sales of real estate 27.1 — 0.16 — 27.5 214.8 0.16 1.26
Impairment of non-real estate investments (10.3) (28.5) (0.06) (0.17) (37.8) (51.5) (0.22) (0.30)
Impairment of real estate (5.7) (20.6) (0.03) (0.12) (36.5) (189.2) (0.22) (1.11)
Acceleration of stock compensation expense due to executive officer resignations — (1.9) — (0.01) — (1.9) — (0.01)
Total $13.7 $(128.2) $0.09 $(0.75) $(79.3) $(248.8) $(0.47) $(1.45)

Refer to Note 3 – “Investments in real estate” and Note 7 – “Investments” to our unaudited consolidated financial statements in

Market risk

As filed, 5,353 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Interest rate risk

The primary market risk to which we believe we may be exposed is interest rate risk, which may result from many factors,

including government monetary and tax policies, domestic and international economic and political considerations, and other factors

that are beyond our control.

In order to modify and manage the interest rate characteristics of our outstanding debt and to limit the effects of interest rate

risks on our operations, we may utilize a variety of financial instruments, including interest rate hedge agreements, caps, floors, and

other interest rate exchange contracts. The use of these types of instruments to hedge a portion of our exposure to changes in interest

rates may carry additional risks, such as counterparty credit risk and the legal enforceability of hedge agreements. As of September 30,

2024, we did not have any outstanding interest rate hedge agreements.

Our future earnings and fair values relating to our outstanding debt are primarily dependent upon prevalent market rates of

interest. The following tables illustrate the effect of a 1% change in interest rates, assuming a zero percent interest rate floor, on our

fixed- and variable-rate debt as of September 30, 2024 (in thousands):

Annualized effect on future earnings due to variable-rate debt:
Rate increase of 1% $(1,166)
Rate decrease of 1% $1,166
Effect on fair value of total consolidated debt:
Rate increase of 1% $(824,796)
Rate decrease of 1% $945,937

These amounts are determined by considering the effect of the hypothetical interest rates on our borrowings as of

September 30, 2024. These analyses do not consider the effects of the reduced level of overall economic activity that could exist in

such an environment. Furthermore, in the event of a change of such magnitude, we would consider taking actions to further mitigate our

exposure to the change. Because of the uncertainty of the specific actions that would be taken and their possible effects, the sensitivity

analyses assume no changes in our capital structure.

Equity price risk

We have exposure to equity price market risk because we hold equity investments in publicly traded companies and privately

held entities. All of our investments in actively traded public companies are reflected in our consolidated balance sheets at fair value.

Our investments in privately held entities that report NAV per share are measured at fair value using NAV as a practical expedient to fair

value. Our equity investments in privately held entities that do not report NAV per share are measured at cost less impairments,

adjusted for observable price changes during the period. Changes in fair value of public investments, changes in NAV per share

reported by privately held entities, and observable price changes of privately held entities that do not report NAV per share are

classified as investment income in our consolidated statements of operations. There is no assurance that future declines in value will

not have a material adverse effect on our future results of operations. The following table illustrates the effect that a 10% change in the

value of our equity investments would have on earnings as of September 30, 2024 (in thousands):

Equity price risk:
Fair value increase of 10% $151,933
Fair value decrease of 10% $(151,933)

114

Foreign currency exchange rate risk

We have exposure to foreign currency exchange rate risk related to our subsidiaries operating in Canada. The functional

currencies of our foreign subsidiaries are the local currencies in each respective country. Gains or losses resulting from the translation

of our foreign subsidiaries’ balance sheets and statements of operations are classified in accumulated other comprehensive income

(loss) as a separate component of total equity and are excluded from net income (loss). Gains or losses will be reflected in our

consolidated statements of operations when there is a sale or partial sale of our investment in these operations or upon a complete or

substantially complete liquidation of the investment. The following tables illustrate the effect that a 10% change in foreign currency rates

relative to the U.S. dollar would have on our potential future earnings and on the fair value of our net investment in foreign subsidiaries

based on our current operating assets outside the U.S. as of September 30, 2024 (in thousands):

Effect on potential future earnings due to foreign currency exchange rate:
Rate increase of 10% $223
Rate decrease of 10% $(223)
Effect on the fair value of net investment in foreign subsidiaries due to foreign currency exchange rate:
Rate increase of 10% $40,407
Rate decrease of 10% $(40,407)

The sensitivity analyses assume a parallel shift of all foreign currency exchange rates with respect to the U.S. dollar; however,

foreign currency exchange rates do not typically move in such a manner, and actual results may differ materially.

Our exposure to market risk elements for the nine months ended September 30, 2024 was consistent with the risk elements

presented above, including the effects of changes in interest rates, equity prices, and foreign currency exchange rates.

Controls and procedures

As filed, 979 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of disclosure controls and procedures

As of September 30, 2024, we had performed an evaluation, under the supervision of our principal executive officers and

principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. These controls and

procedures have been designed to ensure that information required for disclosure is recorded, processed, summarized, and reported

within the requisite time periods. Based on our evaluation, the principal executive officers and principal financial officer concluded that

our disclosure controls and procedures were effective as of September 30, 2024.

Changes in internal control over financial reporting

There has not been any change in our internal control over financial reporting during the three months ended September 30,

2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

115

Risk factors

As filed, 4,107 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the information set forth in this quarterly report on Form 10-Q, one should also carefully review and consider the

information contained in the other reports and periodic filings that we make with the SEC, including, without limitation, the information

contained under the caption “Item 1A. Risk factors” in our annual report on Form 10-K for the year ended December 31, 2023. Those

risk factors could materially affect our business, financial condition, and results of operations. The risks that we describe in our public

filings are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we presently deem to be

immaterial, also may materially adversely affect our business, financial condition, and results of operations.

There have been no material changes in our risk factors from those disclosed under the caption “Item 1A. Risk factors” in our

annual report on Form 10-K for the year ended December 31, 2023, except for the following updates:

The increased use of artificial intelligence (“AI”) and automation in life science research and development

(“R&D”) activities may change the uses, space configurations and tenant requirements for our laboratory properties

in currently unforeseen ways.

In recent years, some life science companies have augmented their traditional laboratory-based R&D efforts by

integrating AI, cloud computing, quantum computing and other advanced computational technologies into their R&D programs.

It is expected that such technologies will accelerate and streamline a number of R&D functions, including, for example, through

the targeted design and evaluation of clinical trials and the efficient identification of the most promising drug development

candidates from among multiple possible drugs. In addition, life science companies, like companies in many other industries,

are increasingly integrating new technologies, such as robotics and advanced automation of recurring tasks, into their

businesses, including their R&D activities. It is widely thought that the life science and healthcare industries, like most

industries, are in only the early stages of an advanced technology revolution that may have profound, and largely currently

unknown, impacts on their businesses, including the processes and strategies underlying R&D and commercialization of new

products.

We have always strived to provide our tenants with state-of-the-art laboratory facilities incorporating cutting-edge

infrastructure features (including energy delivery, environmental, sustainability, security, and waste disposal features) to enable

our tenants to perform at the highest levels. It is currently unknown how the ongoing adoption of advanced technologies and

automation in the life science industry will impact the optimal space configurations and infrastructure features of the “laboratory

of the future,” and we may face new tenant requirements and requests that will require significant expenditures that may not be

entirely recoverable through increased rents. For example, the adoption of AI by our tenants may lead to infrastructure

requirements that our buildings currently do not accommodate, such as increased power needs due to high-performance

computing. Infrastructure upgrades may necessitate substantial capital expenditures and could potentially impact the

environmental footprint of our building operations.

116

If technological developments result in a reduction or reconfiguration in space requirements by our tenants, demand by

individual tenants and prospective tenants for space may decrease over time. If we are not able to offset any reduction in demand from

the foregoing developments through repurposing space, property dispositions, or other means, the realization of any of the

aforementioned risks could have a material adverse impact on our revenues, net operating income, results of operations, funds from

operations, operating margins, occupancy, earnings per share, FFO per share, our overall business, and the market value of our

common stock.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-07-01 to 2024-09-30$791.6mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Revenue9 months2024-01-01 to 2024-09-30$2.33bnus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Interest expense3 months2024-07-01 to 2024-09-30$43.5mus-gaap:InterestExpense
Interest expense9 months2024-01-01 to 2024-09-30$130.2mus-gaap:InterestExpense
Net income3 months2024-07-01 to 2024-09-30$167.9mus-gaap:NetIncomeLoss
Net income9 months2024-01-01 to 2024-09-30$385.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-07-01 to 2024-09-30$0.96us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2024-01-01 to 2024-09-30$2.18us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-07-01 to 2024-09-30$0.96us-gaap:EarningsPerShareBasic
Basic EPS9 months2024-01-01 to 2024-09-30$2.18us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-07-01 to 2024-09-30172,058,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2024-01-01 to 2024-09-30172,007,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2024-01-01 to 2024-09-30$1.23bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Dividends paid9 months2024-01-01 to 2024-09-30$671.4mus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2024-09-30$562.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Total assetsAt period end2024-09-30$38.49bnus-gaap:Assets
Total liabilitiesAt period end2024-09-30$15.78bnus-gaap:Liabilities
Long-term debtAt period end2024-09-30$12.69bnus-gaap:LongTermDebt
Shareholders' equityAt period end2024-09-30$18.22bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001035443-24-000298. Last ingested by Listed: Nov 3, 2026, 21:07 ET. Listed shows no prices and gives no investment advice.